Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02314117 · ClinicalTrials.gov registry record · Phase 3
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 645
- Enrollment target
NCT02314117 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 645 participants.
The verdict
NCT02314117, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 645 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.
Interventions
- DRUG Placebo
- DRUG Capecitabine
- DRUG Cisplatin
- DRUG Fluorouracil
- DRUG Ramucirumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 645 participants |
| Start Date | 2015-01-20 |
| Est. Completion | 2020-08-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02314117
The ClinicalTrials.gov registry entry for NCT02314117 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 645 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02314117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02314117 about?
NCT02314117 is a clinical study titled "A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer". The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.
What is the current status of trial NCT02314117?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 645 participants. The study started on 2015-01-20. Estimated completion is 2020-08-14.
What interventions are being tested in trial NCT02314117?
The interventions under investigation include: Placebo (DRUG), Capecitabine (DRUG), Cisplatin (DRUG), Fluorouracil (DRUG), Ramucirumab (DRUG).
Who is sponsoring clinical trial NCT02314117?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.